Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force

Executive Summary

Andrx plans to launch extended-release lovastatin in 2002 for hyperlipidemia with three years of exclusivity, President Elliot Hahn, PhD, announced March 28 at the Banc of America Securities Healthcare Conference in Las Vegas.
Advertisement

Related Content

Andrx lovastatin XL approved
Andrx lovastatin XL “approvable”
Cholesterol Therapy Guidelines Stress Need To Consider Cost, Treat To Goal
Andrx/Aventis Settle With FTC: Agency Says Cardizem CD Generic Not Delayed
Elan Seeks Frovelan Partner, More Sales Reps For Migraine Product Launch
Vascular Dementia May Not Be Distinct Clinical Entity, FDA Cmte. Says
AstraZeneca Awaits "Orange Book" Listing For Three Prilosec Patents
Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems
Andrx
Andrx
Advertisement
UsernamePublicRestriction

Register

PS037571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel